EMA launched ongoing evaluation of Sputnik V vaccine

(ČIA) The European Medicines Agency (EMA) has launched an ongoing evaluation of the Sputnik V anti-COVID-19 vaccine. The vaccine was developed by the Russian Institute of Epidemiological and Microbiological Research in Moscow. The applicant in the EU will be R-Pharm Germany. Irena Storová, director of the State Institute for Drug Control (SÚKL), said that the interim evaluation would show whether the data from the Russian clinical study were at a sufficient level to ask the EMA to evaluate the vaccine when applying for registration. The information was published by SÚKL.



Register newsletter

Get to know about Nordic Chamber, our press releases and all news, straight to your inbox.